Ocular Therapeutix appoints Donald Notman as COO, retains CFO role

OCULAR THERAPEUTIX, INC

Donald Notman, age 65, appointed COO on August 29, 2024; continues as CFO and principal financial and accounting officer.
Notman has served as CFO since September 2017; prior roles include CFO of Thrasos Therapeutics and Managing Director at Leerink Swann.
No arrangements or family relationships with other directors/officers; no related party transactions under Item 404(a).

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Donald Notman

Chief Operating Officer

OCUL · OCULAR THERAPEUTIX, INC

Effective: 2024-08-29
Filed: September 3, 2024, 7:59 PM ET

On August 29, 2024, the board of directors of Ocular Therapeutix, Inc. (the “Company”) appointed Donald Notman to serve as Chief Operating Officer of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Donald Notman was appointed as Chief Operating Officer at OCULAR THERAPEUTIX, INC.

Action: appointed
Role: Chief Operating Officer

Exact text from the filing

On August 29, 2024, the board of directors of Ocular Therapeutix, Inc. (the “Company”) appointed Donald Notman to serve as Chief Operating Officer of the Company.

View on SEC.gov

OCULAR THERAPEUTIX, INC filing history →

Source: SEC EDGAR

accession 0001104659-24-096021

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.